Kelion A D, Webb T P, Gardner M A, Ormerod O J, Shepherd G L, Banning A P
Department of Cardiology, John Radcliffe Hospital, Oxford, UK GlaxoSmithKline Research and Development, Greenford, Middlesex, UK.
Heart. 2002 Feb;87(2):115-20. doi: 10.1136/heart.87.2.115.
The "warm up" effect in angina may represent ischaemic preconditioning, which is mediated by adenosine A(1) receptors in most models.
To investigate the effect of a selective A(1) agonist, GR79236 (GlaxoSmithKline), on exercise induced angina and ischaemic left ventricular dysfunction in patients with coronary artery disease.
A double blind crossover study.
25 patients with multivessel coronary artery disease.
On mornings one week apart, patients received intravenous GR79236 10 microgram/kg or placebo, and then carried out two supine bicycle exercise tests separated by 30 minutes. Equilibrium radionuclide angiography was done before and during exercise.
The onset of chest pain or 1 mm ST depression was delayed and occurred at a higher rate-pressure product during the second exercise test following either placebo or GR79236. Compared with placebo, GR79236 did not affect these indices during equivalent tests. GR79236 reduced resting global ejection fraction from (mean (SD)) 63 (7)% to 61 (5)% (p < 0.05) by a selective reduction in the regional ejection fraction of "ischaemic" left ventricular sectors (those where the ejection fraction fell during the first exercise test following placebo). Ischaemic sectors showed increased function during the second test following placebo (72 (21)% v 66 (20)%; p = 0.0001), or during the first test following GR79236 (69 (21)% v 66 (20)%; p = 0.0001). Sequential exercise further increased the function of ischaemic sectors even after drug administration.
GR79236 failed to mimic the warm up effect, and warm up occurred even in the presence of this agent. This suggests that ischaemic preconditioning is not an important component of this type of protection. The complex actions of the drug on regional left ventricular function at rest and during exercise suggest several competing A(1) mediated actions.
心绞痛中的“热身”效应可能代表缺血预处理,在大多数模型中这是由腺苷A(1)受体介导的。
研究选择性A(1)激动剂GR79236(葛兰素史克公司)对冠心病患者运动诱发心绞痛和缺血性左心室功能障碍的影响。
双盲交叉研究。
25例多支冠状动脉疾病患者。
在间隔一周的早晨,患者接受静脉注射10微克/千克GR79236或安慰剂,然后进行两次间隔30分钟的仰卧位自行车运动试验。在运动前和运动期间进行平衡放射性核素血管造影。
在服用安慰剂或GR79236后的第二次运动试验中,胸痛发作或ST段压低1毫米的时间延迟,且在更高的心率-血压乘积时出现。与安慰剂相比,GR79236在同等试验中未影响这些指标。GR79236通过选择性降低“缺血性”左心室节段(即服用安慰剂后第一次运动试验中射血分数下降的节段)的局部射血分数,使静息整体射血分数从(均值(标准差))63(7)%降至61(5)%(p<0.05)。缺血节段在服用安慰剂后的第二次试验中(72(21)%对66(20)%;p=0.0001),或在服用GR79236后的第一次试验中(69(21)%对66(20)%;p=0.0001)功能增强。即使在给药后,连续运动进一步增强了缺血节段的功能。
GR79236未能模拟热身效应,即使在使用该药物的情况下仍出现了热身现象。这表明缺血预处理不是这种类型保护的重要组成部分。该药物在静息和运动时对局部左心室功能的复杂作用提示了几种相互竞争的A(1)介导的作用。